Key Principles in Glioblastoma Therapy
暂无分享,去创建一个
S. Kesari | B. Carter | Clark C. Chen | K. Ng | Bartek Jiri
[1] K. Aboody,et al. Concise Review: Stem Cells As an Emerging Platform for Antibody Therapy of Cancer , 2010, Stem cells.
[2] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[3] L. Chin,et al. Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma Therapy , 2010, PloS one.
[4] J. Kuo,et al. The cancer stem cell paradigm: a new understanding of tumor development and treatment , 2010, Expert opinion on therapeutic targets.
[5] R. McLendon,et al. Integrin alpha 6 regulates glioblastoma stem cells. , 2010, Cell stem cell.
[6] Serban Nacu,et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. , 2010, Cancer cell.
[7] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[8] S. Horvath,et al. EGFR Signaling Through an Akt-SREBP-1–Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic Therapy , 2009, Science Signaling.
[9] C. Brennan,et al. Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations , 2009, PloS one.
[10] Paul S Mischel,et al. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis , 2009, Proceedings of the National Academy of Sciences.
[11] Michael J. Emanuele,et al. A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.
[12] Austin G Smith,et al. CD133 (Prominin) Negative Human Neural Stem Cells Are Clonogenic and Tripotent , 2009, PloS one.
[13] H. Fine,et al. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. , 2009, Cell stem cell.
[14] M. Stratton,et al. The cancer genome , 2009, Nature.
[15] Ji Luo,et al. Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.
[16] Arturo Alvarez-Buylla,et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. , 2009, Cancer cell.
[17] Anna M. Krichevsky,et al. miR-21: a small multi-faceted RNA , 2008, Journal of cellular and molecular medicine.
[18] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[19] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[20] R. McLendon,et al. Targeting cancer stem cells through L1CAM suppresses glioma growth. , 2008, Cancer research.
[21] Santosh Kesari,et al. Malignant gliomas in adults. , 2008, The New England journal of medicine.
[22] Jian Wang,et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells , 2008, International journal of cancer.
[23] Peter Canoll,et al. Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. , 2008, Neurosurgery.
[24] Yuri Kotliarov,et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. , 2008, Cancer cell.
[25] Sreenath V. Sharma,et al. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. , 2007, Genes & development.
[26] Keith L. Ligon,et al. Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.
[27] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[28] C. Der,et al. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.
[29] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[30] D. Louis. WHO classification of tumours of the central nervous system , 2007 .
[31] Mark W. Dewhirst,et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.
[32] Thomas D. Wu,et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.
[33] Koji Yoshimoto,et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.
[34] W. Kaelin. The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.
[35] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[36] R. Henkelman,et al. Identification of human brain tumour initiating cells , 2004, Nature.
[37] B. Druker. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML , 2002, Oncogene.
[38] D. Steindler,et al. Human cortical glial tumors contain neural stem‐like cells expressing astroglial and neuronal markers in vitro , 2002, Glia.
[39] I. Weinstein. Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.
[40] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[41] D. Felsher,et al. Reversible tumorigenesis by MYC in hematopoietic lineages. , 1999, Molecular cell.
[42] L. Chin,et al. Essential role for oncogenic Ras in tumour maintenance , 1999, Nature.
[43] D. Felsher,et al. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[44] K. Yokoyama,et al. Transcriptional control of the endogenous MYC protooncogene by antisense RNA. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[45] E. Alexander,et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.